Is there a generic slynd?

What is the current status of siltuximab generics?

Siltuximab, also known as Sylvant, is a medication used to treat multicentric Castleman disease [1]. There are no approved generics for siltuximab available yet. According to DrugPatentWatch.com, the patent for siltuximab is set to expire in [2025] [2].

Why is it hard to find a generic siltuximab?

The manufacturer of Sylvant, Janssen Biotech, has taken steps to protect their market share. Patent protection can be a significant barrier to entry for generic manufacturers.

Can biosimilars enter the market before patent expiry?

The answer is no, in this case. Biosimilars are similar to generics but specifically designed for biologic medication like siltuximab. In the US, biosimilars are regulated by the FDA, and the development process can be quite lengthy. The FDA will only approve biosimilars that meet rigorous requirements for efficacy, safety, and purity.

Sources:

[1] National Institute of Health. Siltuximab [www.ncbi.nlm.nih.gov].

[2] DrugPatentWatch.com (2023). Sylvant [www.drugpatentwatch.com].